Off-Label Approaches to Therapeutic Challenges in Dermatology, with Adam Friedman, MD

During the Dermatology Education Foundation (DERM) 2025 NP/PA CME Conference, Adam Friedman, MD, from the George Washington University School of Medicine & Health Sciences Department of Dermatology, spoke about off-label approaches to therapeutic challenges in conditions such as lichen planus.

Friedman spoke with HCPLive about the lack of US Food and Drug Administration (FDA)-approved treatments for lichen planus and other lichenoid dermatitides, advocating for off-label use of JAK inhibitors and other treatments like oral retinoids and doxycycline. He also highlighted the potential of JAK inhibitors in autoimmune skin disease treatment, noting conditions such as cutaneous lupus, dermatomyositis, and morphia, noting ongoing clinical studies and personal successes. Click here to watch the full interview.